Global Industry Analysts, Inc., Oct 2006, Pages: 563
This report analyzes the worldwide markets for BreastCancerTherapeutics in US$ Million. The major product segments analyzed are Hormonal Therapy, Chemotherapy, and InnovativeTherapy. The report
Espicom Business Intelligence Ltd, Nov 2009, Pages: 160
The prostate cancer market is on the verge of considerable change with the imminent arrival of new targeted therapies that will prolong patient survival.
Prostate cancer (PCA) is the second leading
MP Advisors, Feb 2011, Pages: 90
to understand how global companies are adapting to this difficult situation, as the challenge is mammoth. There are only two avenues of growth for global pharma companies - Innovation and Emerging markets
Life Science Intelligence, Inc., Dec 2011, Pages: 605
and sedation and improved patient outcomes in Operating Rooms (ORs) and Intensive Care Units (ICUs)
- The next major step in the treatment of early breastcancer: replacing lumpectomy with a percutaneous
MP Advisors, Jan 2011, Pages: 391
with explanations of how a drug will perform in its therapy area and how the market will shape up due to competition. Global Bio-Pharma Outlook 2011
India Pharma: Macro View
Para IV - The New India Advantage
Espicom Business Intelligence Ltd, Dec 2009, Pages: 318
of breast and prostate cancers exceeding the number of new lung cancer cases.
In the last five years, a number of high value cancertherapies have lost market exclusivity in the US, opening
Spectra Intelligence, Sep 2007, Pages: 350
for market potential and growth;
- Benchmark analytics for current research themes and futuretherapy areas;
- Evaluation of the key drivers and predictors of growth and innovation in gynaecology;
- In-depth assessment
Espicom Business Intelligence Ltd, July 2007, Pages: 306
.
Division of Molecular Medicine
Division of Medical Oncology & Therapeutics Research
Duke University
Duke Comprehensive Cancer Center.
Center for Molecular and Biomolecular Imaging (CMBI)
Pulse Shaping
